



CADTH: *Health Technology Assessment*

2018 CANM-CAMRT JOINT ANNUAL CONFERENCE

Harindra Wijeyesundera MD PhD FRCPC
Vice President Medical Devices & Clinical Interventions, CADTH
Associate Professor, Department of Medicine, & Institute for Health Policy,
Management and Evaluation (iHPME) University of Toronto
Interventional Cardiologist, Schulich Heart Center,
Sunnybrook Health Sciences Center
Scientist, Sunnybrook Research Institute

CADTH

CANM
ACMN

CANM-CAMRT JOINT ANNUAL
CONFERENCE
MARCH 22-24, 2018
VANCOUVER, B.C.

I do not have a financial interest, arrangement or affiliation including receipt of honoraria or expenses with a commercial organization that may have a direct interest in the subject matter of my presentation.

OUTLINE

1. What is CADTH?
2. Current framework for medical device assessment in Canada
 - a. Overview of the life-cycle of health technologies
 - b. When and how health technologies assessments are made
 - c. Understanding the definition of value
3. Short-comings of traditional approach of HTA & transition to health technology management

CADTH

is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence about the optimal use of drugs and medical devices.

Our Programs and Services



DRUG REIMBURSEMENT RECOMMENDATIONS

- CADTH Common Drug Review (CDR)
- CADTH pan-Canadian Oncology Drug Review (pCODR)



HEALTH TECHNOLOGY MANAGEMENT PROGRAM

- Rapid Response Service
- Health Technology Assessment Service
- Optimal Use Service
- Environmental Scanning
- Horizon Scanning



OTHER PROGRAMS AND SERVICES

- Scientific Advice



KNOWLEDGE MOBILIZATION AND LIAISON OFFICERS

- Located in jurisdictions across Canada
- Understand the needs and priorities of local decision-makers
- Provide advice and tools to help turn evidence into policy and practice

CADTH

The background of the slide is a solid purple color. Overlaid on this background are faint, semi-transparent images of medical equipment. On the right side, there is a close-up of a glucometer (blood sugar meter) with a test strip inserted into its slot. The meter has a small screen at the top and two buttons labeled 'M' and 'S'. In the center-left, there is a syringe with a needle. In the bottom-left corner, there is a small, rectangular medical device, possibly a patch or a small monitor.

was created to build Canada's capacity to use evidence as the basis for sound health care decisions.


This strategic imperative remains a cornerstone of our work.

Current framework for medical device assessment in Canada



Current framework for medical device assessment in Canada

- Canada is a federal system that is highly decentralized
- Regulatory approval to enter the marketplace is conducted federally by Health Canada
 - Special access/compassionate use
- Once in the market place, funding for medical devices is determined and provided at the provincial/territorial level
 - Single 3rd party payer
- Administration of health care delivery is done regionally within provinces




Current framework for medical device assessment in Canada



Traditional Health Technology Assessment

When: Life Cycle of a Technology



Funding decisions

- Based on an explicit decision making framework
 - *Comparative Effectiveness*
 - *Comparative Safety*
 - Consistency with social, ethical principles
 - Efficiency
 - **VALUE**
 - **Not synonymous with cost**

Value

PERFORMANCE MEASURES

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures




A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines

- High value health care
 - Positive results (improved patient outcomes, safety, and satisfaction) at a total cost that is reasonable and affordable

Value


- How to calculate “value”?
 - Metric
 - Incremental cost/per unit of health gained
 - ICER
 - Depends on the jurisdiction and health care system
 - Canada – fixed budget

Cost/health gain for each technology






Cost/health gain for each technology





Cost/health gain for each technology



Societal Health Improves

50k-150k

Threshold

Funded

Budget

Not Funded

Health care expenditure

Displaced technology


New technology

Cost-effectiveness Analysis

- Value of a technology is calculated by formal cost-effectiveness analyses
 - Includes all relevant comparators and determines the incremental cost per unit of health gained (ie value)

Ok.....but...

- Does an HTA lead to adoption???



Horizon
Scanning

HTA/
Optimal
Use
products


Knowledge
mobilization,
Implementation
support

delisting

(Future) Role of CADTH

- Transforming from a **health technology assessment** agency to a **health technology management** agency


PASSIVE* vs *ACTIVE **ROLE IN DEVICE** **MANAGEMENT**



Horizon Scanning


Pre-regulatory

- Horizon Scanning
 - Provide update on products 2-5 years in the pipeline
 - Newsletters
 - Informed from multiple sources including industry
 - Meant to “prepare the system”
 - inform topic selection for larger health technology assessments



HTA/ Optimal Use products

Topic Identification and Prioritization



Topic Identification and Prioritization

- Prioritization Process
 - Phase I filter:
 - unmet need



RELEVANCE

- Clinical impact
- Economic impact
- Population impact
- Jurisdictional interest
- Equity



Topic Identification

- Once topics have been ranked by priority, 2-3 per quarter will go forward as HTA
- Detailed Scoping


CADTH Deliberative Framework

- Multi-criteria approach:
 - Relevance and Unmet Need
 - Benefits
 - Harms
 - Patient perspective
 - Economic impact
 - Implementation
 - Legal
 - Ethical
 - Environmental impact

*CADTH will
produce an
evidentiary
bundle across
these domains*

- External expert committee makes recommendations


Process




Project Components

- Protocol
 - **“fit for purpose”**
- Science review
 - Clinical systematic review
 - Economic analysis
 - Reviews of additional considerations
 - Ethical, legal, social implications
 - Implementation issues
 - Patient perspectives
- Recommendations

General Timelines





**Knowledge
mobilization,
Implementation
support**

Knowledge Mobilization

- Development of key messages based on recommendations and HTA report
 - why there is a gap between the way a technology is used and the evidence
- Early and ongoing identification and engagement of stakeholder groups
 - Partnerships
- Supporting local adaptation

Knowledge Mobilization Tools & Strategies

- Project highlights
- Policy brief
- Optimal Therapy Newsletter
-
-
-
-
-
-
-
- Café Scientifique events




IMPACT

BLOOD GLUCOSE MONITORING FOR PATIENTS WITH TYPE 2 DIABETES



Patients with diabetes who are using insulin
\$144,000,000



*This estimate is based on data from eight publicly funded drug plans in Canada (British Columbia, Manitoba, Newfoundland and Labrador, Ontario, Non-Insured Health Benefits, Nova Scotia, Quebec, and Saskatchewan) plus data from 67% of privately funded drug plans that submitted data to Brogan Inc. Some patients in the dataset could not be classified by province or territory; therefore, the estimate is understated.

Patients with diabetes who are not using insulin
\$188,000,000

The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent not-for-profit agency that provides Canada's federal, provincial, and territorial health care decision makers with credible, impartial advice and evidence-based information about the effectiveness and efficiency of drugs and other health technologies.

If practice changes to reflect the evidence, more than \$150 million* would be freed up to be spent elsewhere. Patient health would not be affected negatively.

Opportunities

- Greater alignment of regulatory and adoption process
 - Use special access as an input for topic selection
- Initiate earlier reimbursement assessments
 - Challenges is quality of evidence
 - Need for reassessments
 - ? Conditional approval
- Implementation
 - Regional hubs
 - Informing value based procurement
- Disinvestment

Summary

- Regulatory and reimbursement landscape for medical devices in Canada remains complex
 - CADTH is transforming from a HTA agency to health technology management
- Opportunities exists to streamline process for selected high impact, disruptive technologies

Connect With Us



@CADTH_ACMTS



linkedin.com/company/cadth



slideshare.net/CADTH-ACMTS



youtube.com/CADTHACMTS



cadth.ca/photoblog



requests@cadth.ca